Vital

Peptides

Tesamorelin Dosage Units: Egrifta WR, SV, and Syringe Math

Tesamorelin dosage units explained from the FDA labels: the Egrifta WR dose of 1.28 mg (16 units), the Egrifta SV dose of 1.4 mg (35 units), why 2 mg is not a universal number, and how the unit math works for any vial.

Last reviewed

The Vital angle

Vital's reconstitution calculator takes the vial mass in mg or mcg, the water in mL or syringe units, and the dose from your prescriber, then shows the concentration, the U-100 draw with its mL, and the doses per vial. It warns when a draw is more than a 1 mL syringe holds, and each dose log keeps the source type, lot number, expiration date, injection site, and symptoms.

Tesamorelin dosage units: the short answer

Tesamorelin dosage units depend on which product you have. The FDA label for Egrifta WR lists 1.28 mg once daily, which is 0.16 mL of the mixed solution. On a U-100 insulin syringe scale, 0.16 mL is the 16-unit line. The label for Egrifta SV lists 1.4 mg once daily, which is 0.35 mL, or the 35-unit line.

The milligram numbers differ because the formulations differ, not because one dose is "stronger." The Egrifta WR label says that the exposure from 1.28 mg of Egrifta WR is similar to the exposure from 2 mg of the older 1 mg per vial Egrifta. So a milligram number from one product does not carry over to another product. Tesamorelin is FDA-approved for one use only: to reduce excess abdominal fat in adults with HIV and lipodystrophy.

This guide shows the label numbers and the unit math. It does not give a dose. Your prescriber sets the dose, and your pharmacist can confirm the draw.

The Egrifta formulations side by side

The table uses the current FDA label for Egrifta WR (revised March 2025) and the DailyMed label for Egrifta SV.

Egrifta WR Egrifta SV
Tesamorelin per vial 11.6 mg 2 mg
Diluent in the kit Bacteriostatic Water for Injection Sterile Water for Injection
Diluent volume 1.3 mL 0.5 mL
Strength after mixing 8 mg per mL 2 mg per 0.5 mL (4 mg per mL)
Label dose 1.28 mg once daily 1.4 mg once daily
Volume per dose 0.16 mL 0.35 mL
Same volume on a U-100 scale 16 units 35 units
Doses per vial 7 daily doses 1 dose
After mixing Room temperature, discard 7 days after mixing Inject right away, discard the rest
Injection site Abdomen, rotate sites Abdomen, rotate sites

Both labels say to use only the diluent in the kit, to swirl the vial and not shake it, and to avoid the navel, scar tissue, and bruises. The Egrifta WR label also says not to refrigerate or freeze the mixed vial.

How the Egrifta WR dose becomes 16 units

The Egrifta WR kit is a 28-day supply. It has 4 vials, a 30 mL bottle of bacteriostatic water, 4 larger syringes for the weekly mixing step, and smaller syringes for the daily injections. You mix one vial a week and draw from it each day for 7 days.

The Instructions for Use describe the daily draw in two steps:

  1. Pull the plunger to the 18 mark (0.18 mL).
  2. Push the plunger slowly up to exactly the 16 mark (0.16 mL), which also removes air.

The marks on the daily syringe are hundredths of a mL, so "16" means 0.16 mL. That is the same volume as 16 units on a U-100 insulin syringe, where 1 unit is 0.01 mL. The math is simple: 1.28 mg divided by 8 mg per mL is 0.16 mL, and 0.16 mL times 100 is 16 units.

Use the syringes that come in the kit, and follow the Instructions for Use. If your syringe has a different scale, such as U-40, the same mark holds a different volume. Our guide to U-40 vs U-100 syringes explains that error.

Why "tesamorelin 2 mg" is not a universal number

Many calculators online say that the tesamorelin dose is 2 mg. That number comes from the older Egrifta formulation of 1 mg per vial. The current Egrifta WR label gives 1.28 mg, and the Egrifta SV label gives 1.4 mg. The Egrifta WR label bases its dose on comparable bioavailability with the older product, not on equal milligrams.

This has two results:

  • If you switch between Egrifta products, the milligrams and the volume both change. Read the label of the product in your hand.
  • A milligram number on a non-Egrifta vial has no label behind it. The labels apply only to the approved products.

Unit math for a compounded or research vial

Our tesamorelin guide explains why compounded tesamorelin has an unclear legal status. Egrifta moved to regulation as a biologic in 2020, and research-labeled vials are not approved drugs. If you have a vial that is not Egrifta, the label numbers above do not apply to it.

The math itself is the same for any vial. The numbers below are hypothetical round numbers that show the method. They are not doses, and they do not match any label.

  1. Concentration (mg per mL) = mg in the vial ÷ mL of water added.
  2. Volume (mL) = amount ÷ concentration.
  3. Units on a U-100 syringe = volume in mL × 100.
Hypothetical vial Water added Concentration Math amount 1 mg Math amount 2 mg
10 mg 1 mL 10 mg/mL 0.10 mL, 10 units 0.20 mL, 20 units
10 mg 2 mL 5 mg/mL 0.20 mL, 20 units 0.40 mL, 40 units
10 mg 3 mL 3.33 mg/mL 0.30 mL, 30 units 0.60 mL, 60 units
5 mg 2.5 mL 2 mg/mL 0.50 mL, 50 units 1.00 mL, 100 units

The table shows why "how many units is 2 mg" has no single answer. The same amount is 20 units in one vial and 100 units in another. The water volume, not the drug, sets the number of units. Confirm every draw with your prescriber or pharmacist, in mL and in units, before you inject.

The free peptide calculator does these steps and also shows doses per vial. For mixing steps, see how to reconstitute peptides with BAC water. To read the strength printed on a vial, see how to read a peptide vial label. For how a given volume looks on a barrel, see how to read an insulin syringe for peptides.

Logging tesamorelin in Vital

Vital is a tracker, not a dosing tool. When you add a vial, you enter the mass in mg or mcg, the water in mL or syringe units, and the dose that your prescriber gave you. Vital then shows the concentration, the draw on the U-100 scale with the mL next to it, and the number of doses in the vial. If a draw is more than a 1 mL syringe holds, Vital shows a warning, so you can check the numbers again with your pharmacist.

The peptide directory in Vital has a tesamorelin profile with its FDA status, evidence level, half-life, known side effects, and a link to the prescribing information. Each dose log can keep the source type, the lot number, the expiration date, the injection site, and any symptoms with a severity. The Egrifta labels tell patients to rotate sites in the abdomen, and the injection site rotation chart shows a simple pattern. If you take a GLP-1 medicine too, the GLP-1 and peptide tracker app guide shows how both appear in one log.

Tesamorelin with ipamorelin

People search for "tesamorelin ipamorelin" because clinics and sellers offer the two together. No published trial has tested this combination, and no label covers it.

The two compounds have a different status:

  • Tesamorelin is approved as Egrifta for HIV lipodystrophy only.
  • Ipamorelin is not an approved drug. In an October 2024 briefing for its compounding advisory committee, the FDA noted that an intravenous ipamorelin trial in patients after bowel surgery reported hypokalemia, hyperglycemia, and two deaths. The FDA said it was unclear whether the deaths were related to ipamorelin. It also said that it found no safety data for ipamorelin by subcutaneous injection.

Both compounds act on the growth hormone system, and the Egrifta labels warn about glucose changes and fluid retention. If a vial holds two compounds, the unit math changes, because each draw delivers both at once. Our CJC-1295 and ipamorelin dosage guide explains that math and the "each vs total" label error.

Warning signs and when to get care

Get emergency care for swelling of the face, lips, tongue, or throat, trouble breathing, or a rash that spreads quickly. The Egrifta WR label reports hypersensitivity reactions such as itching, flushing, hives, and rash.

Call your prescriber soon for any of these:

  • New thirst, frequent urination, or blurred vision, which can be signs of high blood sugar.
  • Swelling in the hands, feet, or ankles, or numbness and tingling in the hand.
  • Joint or muscle pain that does not go away.
  • A red, hot, spreading, or very painful injection site.
  • A dose that you think was too large, for example a draw on the wrong syringe scale.

The label also says that tesamorelin raises IGF-1 and tells prescribers to check IGF-1 and glucose. Bring your dose log to those visits. Our guide on a dose log for doctor visits shows what to record.


Egrifta® (tesamorelin), including Egrifta WR and Egrifta SV, is a trademark of Theratechnologies. Vital is independent and not affiliated with these companies.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Using a 2 mg number for every product

    2 mg is the dose of the older 1 mg per vial Egrifta. The current labels list 1.28 mg for Egrifta WR and 1.4 mg for Egrifta SV, so milligrams do not carry over between products.

  • Unit counts copied from another vial

    The number of units for an amount depends on the water added. The same amount can be 20 units in one vial and 100 units in another.

  • Compounded or research tesamorelin

    The label numbers apply only to the approved Egrifta products. Tesamorelin has been regulated as a biologic since 2020, and research-labeled vials are not approved drugs.

  • Blends with ipamorelin

    No trial has tested the combination. The FDA found no safety data for subcutaneous ipamorelin, and a blend changes the unit math because each draw delivers both compounds.

  • Diabetes or prediabetes

    The Egrifta WR label warns that tesamorelin can cause glucose intolerance and tells prescribers to check glucose before and during treatment.

Frequently asked questions

  • The Egrifta WR label lists 1.28 mg once daily, which is 0.16 mL of the mixed solution. On a U-100 scale, 0.16 mL is the 16-unit line. The kit's Instructions for Use say to draw to the 18 mark and then push back to exactly the 16 mark.

  • It depends on the concentration of the vial. Math example: at 5 mg/mL, 2 mg is 0.40 mL, or 40 units. At 2 mg/mL, it is 1.00 mL, or 100 units. 2 mg is the label dose of the older 1 mg per vial Egrifta only. Confirm any draw with your prescriber or pharmacist.

  • The label says to mix one 11.6 mg vial with 1.3 mL of the bacteriostatic water in the kit, which gives 8 mg per mL. Swirl, do not shake, keep the vial at room temperature, and discard it 7 days after mixing.

  • Egrifta WR is an 11.6 mg vial that you mix once a week for 7 daily doses of 1.28 mg. Egrifta SV is a 2 mg vial that you mix each day for one dose of 1.4 mg (0.35 mL), and you discard the rest.

  • No trial has tested the combination, and no label covers it. Ipamorelin is not an approved drug, and the FDA found no safety data for it by subcutaneous injection. Ask your prescriber before you combine any growth hormone peptides.

  • The FDA approved tesamorelin to reduce excess abdominal fat in adults with HIV and lipodystrophy. The Egrifta WR label says it is not indicated for weight loss management.

Sources

  1. EGRIFTA WR (tesamorelin) for injection, prescribing information and Instructions for Use · U.S. Food and Drug Administration
  2. Label: EGRIFTA SV (tesamorelin) kit · DailyMed, U.S. National Library of Medicine
  3. FDA Briefing Document, Pharmacy Compounding Advisory Committee, October 29, 2024: Ipamorelin-related bulk drug substances · U.S. Food and Drug Administration
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.